Jason Lambrecht, PharmD
Critical Care Medicine · Omaha, NENPI 1134431018
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,248 of the $1,431 with a category attached, or 87.2%. 15 manufacturers reported payments, led by Pfizer at 27.7% of the total. Reporting peaked in 2019 at $399 and has fallen 53.4% since, to $186 in 2025.
Across 70 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$397
- Johnson & Johnson$209
- Astellas Pharma US Inc$183
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$134
- BD$109
- E.r. Squibb & Sons, L.L.C.$73
- plus $326 from 9 others
What the payments were for
- Food & beverage$1,24887%
- Education$18313%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 23 | $397 |
| Johnson & Johnson | 12 | $209 |
| Astellas Pharma US Inc | 3 | $183 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $134 |
| BD | 1 | $109 |
| E.r. Squibb & Sons, L.L.C. | 5 | $73 |
| AbbVie | 4 | $65 |
| Merck | 4 | $62 |
| Boston Scientific | 2 | $44 |
| Melinta Therapeutics, LLC | 2 | $37 |
| AstraZeneca | 1 | $33 |
| Amgen | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Insmed, Inc. | 1 | $19 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HemoSphere$109
How this compares
Too few critical care medicine providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other critical care medicine in Omaha
- Tammy WichmanOmaha$12K
- Steven LiscoOmaha$551
- Andrew PattersonOmaha$454
- Dominique SamuelOmaha$393
- Sabin BistaOmaha$370
- Robert PlambeckOmaha$289
- Kara ReyesOmaha$69
- Zahid IqbalOmaha$52
- Ashley CarneOmaha$37
- Terry BrownOmaha$36
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.